KURA
HEALTHCAREKura Oncology Inc
AI Insight
What's Moving KURA Today?
No stock-specific AI insight has been generated for KURA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.45$12.49
$10.38
Fundamentals
Market Cap$929M
P/E Ratio—
EPS$-3.35
Dividend Yield—
Dividend / Share—
ROE-124.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding88.8M
KURA News
27 articles- Form 4 Kura Oncology Inc For: 22 June By Investing.comInvesting.com Canada·Jun 22, 2026
- Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading planStock Titan·Jun 22, 2026
- Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURATradingView·Jun 11, 2026
- Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLYahoo Finance·Jun 11, 2026
- How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst RevisionsYahoo Finance·Jun 6, 2026
- Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development StrategyYahoo Finance·Jun 3, 2026
- Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AMLYahoo Finance·Jun 2, 2026
- Kura Oncology reports tumor shrinkage in cancer drug trial By Investing.comInvesting.com Canada·May 26, 2026
- Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid TumorsGlobeNewswire·May 26, 2026
- Experimental drug combo shrinks tumors in 77% of advanced cancer patientsStock Titan·May 26, 2026
- Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation SummitYahoo Finance·May 19, 2026
- Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) EstimatesYahoo Finance·May 17, 2026
- Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their ForecastsYahoo Finance·May 15, 2026
- Kura Oncology, Inc. Q1 2026 Earnings Call SummaryMoby·May 13, 2026
- Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising ...Yahoo Finance·May 13, 2026
- Kura Oncology Q1 Earnings Call HighlightsMarketbeat·May 13, 2026
- Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 12, 2026
- Kura Oncology Reports First Quarter 2026 Financial ResultsYahoo Finance·May 12, 2026
- Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 CongressYahoo Finance·May 12, 2026
- Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceYahoo Finance·May 6, 2026
- Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 5, 2026
- Kura Oncology to Report First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- How The Kura Oncology (KURA) Story Is Evolving After Komzifti Launch And Q4 ReassessmentYahoo Finance·May 4, 2026
- Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AMLGlobeNewswire Inc.·Apr 24, 2026
- Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswire Inc.·Apr 17, 2026
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
All 27 articles loaded
Price Data
Open$10.18
Previous Close$10.38
Day High$10.66
Day Low$10.18
52 Week High$12.49
52 Week Low$5.45
52-Week Range
$5.45$12.49
$10.38
Fundamentals
Market Cap$929M
P/E Ratio—
EPS$-3.35
Dividend Yield—
Dividend / Share—
ROE-124.7%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding88.8M
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—